A peptide can be studied for years without ever becoming a drug candidate.

“Research peptide” describes how a compound is being studied or supplied. Formal drug development starts later, when a sponsor selects a candidate and begins building the pharmacology, safety, manufacturing, and regulatory evidence needed to move it toward human trials and, eventually, possible FDA approval.

That gap is easy to miss. A compound can have published laboratory data, animal studies, or even a long research history without ever entering a structured development program.

This guide follows what happens once a peptide does enter that process, from candidate selection and optimization through preclinical work, clinical trials, manufacturing controls, and FDA review. It also explains what makes peptide development different from small-molecule drug discovery and why many candidates never reach approval.

What Stages Does a Peptide Go Through Before Potential FDA Approval?

A peptide drug candidate usually moves through discovery and optimization, preclinical development, clinical trials, regulatory review, and, if the evidence supports it, FDA approval.

Those stages overlap rather than unfolding as a perfectly straight sequence. Researchers may return to formulation, manufacturing, or candidate optimization when later studies reveal problems that need to be solved.

FDA’s drug development process provides the general framework used in the table below.

Stage	What Happens
Discovery and candidate optimization	Target identification or validation, peptide screening and design, potency and selectivity testing, stability work, and candidate selection
Nonclinical (preclinical) development	In vitro, in vivo, and increasingly New Approach Methodology (NAM) studies examine pharmacology, toxicology, pharmacokinetics, and other questions needed before human research
IND preparation and review	The sponsor submits nonclinical data, manufacturing information, and proposed clinical protocols before starting applicable U.S. clinical studies
Clinical development	Phase I through III studies progressively characterize human pharmacology, safety, and effectiveness
Marketing application and FDA review	FDA evaluates clinical evidence, nonclinical evidence, labeling, and manufacturing and quality information
Approval and post-market monitoring	An approved product enters continued safety surveillance and may undergo additional post-approval studies

In vitro and in vivo studies aren’t separate stages that come before preclinical research. They can both be part of the preclinical stage.

FDA’s preclinical research framework includes in vitro and in vivo testing within nonclinical development, alongside newer non-animal methods. So peptide development isn’t simply “discovery, then cells, then animals.” Different models are used throughout preclinical work to answer different questions.

Is Every Research Peptide a Drug Candidate?

No. A peptide can be studied for years without ever entering a formal drug-development program.

A sponsor has to deliberately select a candidate and begin building the evidence and controls needed to advance it. That includes reproducible manufacturing, analytical characterization, nonclinical studies, regulatory planning, and, if development continues, an IND-supported clinical program.

A peptide sold or studied for laboratory research may never have entered that process at all. Research status and drug-candidate status aren’t interchangeable.

What Happens During Peptide Drug Discovery?

Peptide drug discovery starts by finding or designing a sequence that can affect a biological target in a useful and reproducible way.

That starting point can come from a naturally occurring peptide, a screening library, structural modeling, or a sequence designed around a specific biological hypothesis.

Once researchers find a promising candidate, they begin optimizing it.

They may try to improve how strongly it binds its target, how selectively it acts, and how much peptide is needed to produce the intended biological response. They also look at properties that become important outside a simple assay, such as how quickly enzymes break it down, whether it stays soluble, and whether it tends to aggregate.

A peptide can look excellent in a receptor assay and still be a poor drug candidate if it degrades too quickly, behaves unpredictably in solution, or can’t be manufactured consistently.

Researchers can also modify the sequence or chemistry to improve half-life, clearance, membrane permeability, stability, or manufacturability while trying to preserve the activity that made the peptide interesting in the first place.

That optimization step is where a promising research sequence starts to be tested as a realistic development candidate rather than just an interesting laboratory finding.

What Happens During Preclinical Peptide Development?

Preclinical peptide development tests whether a drug candidate has enough pharmacology, safety, and exposure data to justify moving toward human studies.

Researchers use a mix of in vitro systems, animal models, and newer non-animal approaches to study questions such as:

• How the peptide acts on its intended target
• How long it stays in the body
• Where it distributes
• How it is metabolized and cleared
• Which toxic effects appear and at what exposure levels
• Whether the manufacturing process produces a consistent material

Does Preclinical Development Always Require Animal Studies?

No. Preclinical development can use animal studies alongside validated non-animal methods.

FDA refers to many of these approaches as New Approach Methodologies, or NAMs. They can include human-cell systems, organoids, organ-on-chip models, and computational methods.

FDA has been expanding its framework for using scientifically validated NAMs when they can answer a regulatory question reliably and improve the human relevance of the evidence. Animal studies still remain part of many development programs where whole-organism data is needed.

What Is an IND and Why Does It Matter?

An Investigational New Drug application, or IND, is the regulatory submission that allows a sponsor to move an investigational drug toward human clinical testing in the U.S.

An IND typically brings together three major parts of the development program:

• Nonclinical pharmacology and safety data
• Manufacturing and quality information
• The proposed clinical protocol and investigator information

FDA reviews that package to decide whether the proposed study would expose participants to an unreasonable level of risk.

After an initial IND is submitted, the clinical investigation can generally begin after 30 days unless FDA places it on clinical hold or allows it to proceed sooner.

So strong preclinical results aren’t enough on their own. The sponsor also needs a regulatory and manufacturing package that supports taking the candidate into human studies.

What Happens During Clinical Development?

Clinical development is itself staged, though not every program follows an identical three-trial template. FDA’s clinical research framework describes the phases broadly as follows.

Phase	Typical Questions
Phase I	Human pharmacology, tolerability, safety, pharmacokinetics, and sometimes early activity signals
Phase II	Preliminary effectiveness, dose and exposure relationships, and continued safety evaluation
Phase III	Confirmatory effectiveness and broader safety evidence in larger populations
Phase IV / post-market	Additional safety, effectiveness, or other questions studied after approval

Peptide development can raise clinical pharmacology questions that aren’t always as prominent for conventional small molecules.

Researchers may need to study how the peptide moves through the body, whether impaired kidney or liver function changes exposure, whether it interacts with other drugs, whether it affects cardiac electrical activity such as QTc, and whether the immune system recognizes it as foreign.

Immunogenicity deserves particular attention with peptide drugs. An immune response can alter how the drug behaves, reduce its activity, or create additional safety concerns. FDA addressed these and other peptide-specific considerations in draft guidance issued in December 2023.

How Does Peptide Drug Discovery Differ From Small-Molecule Drug Discovery?

Peptides and conventional small molecules create different development problems because their size, chemistry, and structure aren’t the same.

Factor	Small molecules	Peptide drug candidates
Structure	Smaller organic molecules	Larger amino-acid sequences
Target binding	Often fit into defined protein pockets	Can engage broader or flatter surfaces
Stability	Often optimized through medicinal chemistry	Frequently vulnerable to proteolytic breakdown
Cell entry	Often easier	Frequently limited by size and polarity
Oral delivery	Commonly feasible	Often difficult
Manufacturing	Mainly chemical synthesis	Chemical, recombinant, or semi-synthetic
Characterization	Identity, impurities, potency	Also requires close attention to sequence and peptide-specific impurities

One advantage of peptides is that their larger interaction surfaces can sometimes bind biological targets with high affinity and selectivity, including targets that are difficult for smaller molecules to reach effectively.

The same properties can create problems elsewhere. Peptides are often broken down quickly by enzymes, cleared rapidly, and poorly absorbed across cell membranes.

Oral delivery is especially difficult. A peptide taken by mouth has to survive digestive enzymes and the acidic gastrointestinal environment, then cross the intestinal lining in a useful amount.

Proteolytic degradation, molecular size, polarity, and poor epithelial permeability all contribute to the low oral bioavailability seen with many peptides.

Why Does Peptide Manufacturing and Characterization Matter?

A peptide drug has to be manufactured consistently, not just show biological activity in an early experiment.

Peptide synthesis can produce closely related impurities, including incomplete sequences or products with unintended chemical changes. Some peptides can also aggregate or change structure during manufacturing, storage, or formulation.

Researchers therefore need analytical methods that can confirm:

• The correct peptide sequence and identity
• Purity and peptide-related impurities
• Potency or biological activity
• The effects of any intended chemical modifications
• Batch-to-batch consistency
• Aggregation or structural changes where relevant

This work starts during development rather than being added as a final quality check. A candidate that works in the laboratory but can’t be produced reproducibly at larger scale isn’t ready to become a reliable drug product.

Why Do So Many Drug Candidates Stop Before Approval?

Many drug candidates fail after entering clinical development because early promise doesn’t guarantee acceptable results in humans.

A program can stop because the drug doesn’t work well enough, causes safety problems, reaches the wrong tissues, clears too quickly, or proves difficult to manufacture consistently.

Other programs end for reasons that aren’t evidence that the biological idea was wrong. Clinical trials can become impractical, funding can disappear, patents can create problems, or a company can decide to invest in another candidate instead.

Preclinical results therefore answer only the questions tested at that stage. They can’t establish that a peptide will later show acceptable human safety, efficacy, pharmacokinetics, manufacturability, and an overall benefit-risk profile strong enough for approval.

How Long Does Peptide Drug Development Take?

Peptide drug development commonly takes many years from discovery to potential approval.

A program has to move through candidate optimization, nonclinical testing, manufacturing development, human trials, and regulatory review. Problems discovered at any point can send researchers back to reformulate the drug, change the manufacturing process, run additional studies, or redesign a clinical trial.

Some candidates move quickly through individual stages. Others spend years solving stability, delivery, safety, manufacturing, or clinical-development problems before they can advance.

So a development timeline is best understood as a series of scientific and regulatory milestones rather than a fixed countdown to approval.

What Happens During FDA Review?

Once a sponsor has enough nonclinical, clinical, and manufacturing evidence, it can submit a marketing application such as a New Drug Application, or NDA.

FDA then reviews whether the proposed drug:

• Is safe and effective for its intended use
• Has a benefit-risk profile that supports approval
• Has appropriate labeling
• Can be manufactured consistently at the required identity, strength, quality, and purity

The manufacturing review is part of the approval decision, not separate from it. Strong clinical results aren’t enough if the sponsor can’t show that the finished product can be produced reliably.

If FDA approves the application, that approval applies to the specific finished drug product and its labeled use. It doesn’t turn the peptide itself into an FDA-approved compound for every formulation or purpose.

Frequently Asked Questions

This page describes general pharmaceutical research and development processes. It does not describe the development status, safety, or effects of any specific compound, and no therapeutic or efficacy claims are made.